Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Clinical Trial of Neoadjuvant Treatment With Zolendronic Acid Plus Anthracycline and Taxane in Locally Advanced Breast Cancer

Next Previous
Trial Profile

Phase II Clinical Trial of Neoadjuvant Treatment With Zolendronic Acid Plus Anthracycline and Taxane in Locally Advanced Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zoledronic acid (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Trastuzumab
  • Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms ZoNantax

    • Most Recent Events

    • 04 May 2017 Status changed from recruiting to completed.
    • 04 Mar 2013 The antineoplastic regimen was changed to include cyclophosphamide instead of fluorouracil, the duration of zolendronic acid was changed from from 6 to 8 cycles, and other durations were changed from 3 to 4 cycles, according to ClinicalTrials.gov.
    • 04 Mar 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top